We are developing cutting-edge technology with the aim of delivering transformative outcomes for Glioblastoma patients. Glioblastoma has some of the worst outcomes of any cancer, with 5-year survival rates <5%. Innovation in the space has been slow due to the complex nature of this cancer – meaning there are only 6 available FDA-approved therapies for this cancer. Comparatively, breast cancer has 61 FDA-approved treatment options.
A radically different approach to treating this disease is needed. Our founders, a biomedical engineer, and, a neurosurgeon, recognised this unmet need and combined their skills and expertise to develop the concept of the GRACE implant. Using an array of different sciences with an interdisciplinary approach, our talented and specialist team our striving towards delivering longer, better quality lives for brain tumour patients.
CEO & CO-FOUNDER
CLINICAL DIRECTOR & CO-FOUNDER
QUALITY & REGULATORY AFFAIRS MANAGER
PRINCIPAL BIOMATERIALS SCIENTIST
HEAD OF BUSINESS DEVELOPMENT
PRINCIPAL GLIOMA SCIENTIST
Consultant Neurosurgeon at National Hospital for Neurology and Neurosurgery
Consultant Neuro-oncology surgeon at University of Edinburgh
Neurosurgery Registrar in North Thames deanery